Calcium Phosphate Bone Substitutes in the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Review
Source abstract
Abstract
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is characterized by exposed necrotic bone that often progresses with increasing pain and impaired quality of life. Zoledronate, the most potent and widely used bisphosphonate, has been strongly associated with BRONJ development following invasive dental procedures. Given the rising incidence of BRONJ, understanding and implementing effective preventive strategies have become imperative. Biomaterials based on synthetic hydroxyapatite and beta-tricalcium phosphate have been investigated as potential preventive agents. Their therapeutic rationale is supported by two key principles: the well-documented chemical interaction of calcium phosphates with bisphosphonates when used as drug carriers, and the established clinical use of synthetic calcium phosphate biomaterials in dentistry for bone regeneration. This review examines the underlying mechanisms of this preventive therapeutic strategy and evaluates studies investigating synthetic calcium phosphate biomaterials for BRONJ prevention through zoledronate adsorption at jaw wound sites, thereby reducing soft tissue toxicity and promoting healing. The evidence supports the protective effect of these biomaterials as a scientifically grounded preventive approach for BRONJ.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone health and treatments · Chemical Synthesis and Characterization · Oral health in cancer treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Endodontics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
Area of Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, 3000-548 Coimbra, Portugal
Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3000-548 Coimbra, Portugal
Clinical Academic Center of Coimbra (CACC), University of Coimbra, 3000-354 Coimbra, Portugal
Institute of Biophysics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
Medical Imaging and Radiotherapy Department, Polytechnic Institute of Coimbra, ESTESC-Coimbra Health School, 3046-854 Coimbra, Portugal
Institute of Integrated Clinical Practice, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
Institute of Experimental Pathology, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
Laboratory for Evidence-Based Sciences and Precision Dentistry, University of Coimbra, 3000-548 Coimbra, Portugal
Egas Moniz School of Health & Science, Department of Oral Surgery and Oral Medicine, Campus Universitário, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal
Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Campus Universitário, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal
Department of Chemical Engineering, Faculty of Sciences and Technology, University of Coimbra, 3030-790 Coimbra, Portugal
CEMMPRE—Centre for Mechanical Engineering, Materials and Processes, Chemical Engineering Department, University of Coimbra, 3000-548 Coimbra, Portugal
Funding
Fundação para a Ciência e a Tecnologia · Centre for Mechanical Engineering, Materials and Processes
References (94)
Show source-provided references
1. Bisphosphonate Conjugation for Bone Specific Drug Targeting10.1016/j.bonr.2018.06.007 ↗
2. Clodronate in the Management of Different Musculoskeletal Conditions10.23736/S0026-4806.18.05688-4 ↗
3. Antiresorptive Drug-Related Osteonecrosis of the Jaws, Literature Review and 5 Years of Experience10.1007/s12306-018-0548-6 ↗
4. Santora, A.C., and Saag, K.G. (2023). Bisphosphonate. Firestein & Kelley’s Textbook of Rheumatology, 2-Volume Set, Elsevier.
5. Osteoporosis: A Review of Treatment Options
6. Aminobisphosphonates: Reconsideration 25 Years after Their Approval for the Treatment of Osteoporosis
7. Management of Bone Metastasis with Zoledronic Acid: A Systematic Review and Bayesian Network Meta-Analysis10.1016/j.jbo.2023.100470 ↗
8. Direct and Indirect Anticancer Activity of Bisphosphonates: A Brief Review of Published Literature10.1016/j.ctrv.2011.09.003 ↗
9. Metastases and Their Microenvironments: Linking Pathogenesis and Therapy10.1016/j.drup.2005.07.001 ↗
10. Risks and Benefits of Bisphosphonates10.1038/sj.bjc.6604382 ↗
11. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update10.1016/j.joms.2022.02.008 ↗
12. Dental Implant Failure and Medication-Related Osteonecrosis of the Jaw Related to Dental Implants in Patients Taking Antiresorptive Therapy for Osteoporosis: A Systematic Review and Meta-Analysis10.1016/j.eprac.2025.06.003 ↗
13. Medication-Related Osteonecrosis of the Jaw Associated with Implant and Regenerative Treatments: Systematic Review
14. Association between Periodontal Disease, Tooth Extraction, and Medication-Related Osteonecrosis of the Jaw in Women Receiving Bisphosphonates: A National Cohort-Based Study10.1002/JPER.21-0611 ↗
15. Association between Periodontitis and Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis10.1111/jop.12963 ↗
16. Periodontal Disease and Bisphosphonates Induce Osteonecrosis of the Jaws in the Rat10.1002/jbmr.379 ↗
17. Stelea, C.G., Bologa, E., Boișteanu, O., Platon, A.L., Stelea, Ș.O., Gelețu, G.L., Onică, C.A., Șulea, D., Ciofu, M.L., and Costan, V.V. (2025). Bisphosphonate-Related Osteonecrosis of the Jaw: A 10-Year Analysis of Risk Factors and Clinical Outcomes. J. Clin. Med., 14.10.20944/preprints202505.1868.v1 ↗
18. Treatment Strategies and Outcomes of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) with Characterization of Patients: A Systematic Review10.1016/j.ijom.2015.01.026 ↗
19. Clinical Considerations for Medication-Related Osteonecrosis of the Jaw: A Comprehensive Literature Review10.1186/s40729-021-00323-0 ↗
20. Osteonecrosis of the Jaw in Patients with Dental Prostheses Being Treated with Bisphosphonates or Denosumab10.1016/j.jpor.2014.08.001 ↗
21. Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons10.11005/jbm.2015.22.4.151 ↗
22. Antiresorptive Agent-Related Osteonecrosis of the Jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw10.1007/s00774-016-0810-7 ↗
23. Early Bone Healing Events in the Human Extraction Socket10.1054/ijom.2002.0292 ↗
24. Fogelman, I., Van Der Wall, H., and Gnanasegaran, G. (2012). Radionuclide and Hybrid Bone Imaging, Springer.10.1007/978-3-642-02400-9 ↗
25. The Healing Socket and Socket Regeneration
26. Gingival Fibroblasts and Medication-Related Osteonecrosis of the Jaw: Results by Real-Time and Wound Healing in Vitro Assays10.1016/j.jcms.2019.06.004 ↗
27. Inflammation Can Be a High-Risk Factor for Mucosal Nonunion of MRONJ by Regulating SIRT1 Signaling When Treated with an Oncologic Dose of Zoledronate10.2147/DDDT.S456811 ↗
28. Effect of Zoledronic Acid on Oral Fibroblasts and Epithelial Cells: A Potential Mechanism of Bisphosphonate-associated Osteonecrosis10.1111/j.1365-2141.2008.07504.x ↗
29. Inhibition of Oral Mucosal Cell Wound Healing by Bisphosphonates10.1016/j.joms.2008.01.026 ↗
30. Influence of Bisphosphonates on Endothelial Cells, Fibroblasts, and Osteogenic Cells10.1007/s00784-009-0266-4 ↗
31. A Novel Bioassay Model to Determine Clinically Significant Bisphosphonate Levels
32. Bullock, G., Miller, C.A., McKechnie, A., and Hearnden, V. (2021). A Review Into the Effects of Pamidronic Acid and Zoledronic Acid on the Oral Mucosa in Medication-Related Osteonecrosis of the Jaw. Front. Oral Health, 2.10.3389/froh.2021.822411 ↗
33. Osteonecrosis of the Jaw: Effect of Bisphosphonate Type, Local Concentration, and Acidic Milieu on the Pathomechanism10.1016/j.joms.2010.07.017 ↗
34. Bisphosphonate-Associated Osteonecrosis of the Mandible: Reliable Soft Tissue Reconstruction Using a Local Myofascial Flap10.1007/s00784-011-0596-x ↗
35. A Systematic Review of Microsurgical Reconstruction of the Jaws Using Vascularized Fibula Flap Technique in Patients with Bisphosphonate-Related Osteonecrosis10.1590/S1678-77572011000400001 ↗
36. The Effects of Ozone Application on Genotoxic Damage and Wound Healing in Bisphosphonate-Applied Human Gingival Fibroblast Cells10.1007/s00784-017-2163-6 ↗
37. Porcaro, G., Caccianiga, P., Bader, A.A., Caccianiga, G., Porcaro, G., Caccianiga, P., Bader, A.A., and Caccianiga, G. (2022). Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Er:YaG Laser and Ozone Therapy: A Case Series. Inventions, 7.10.3390/inventions7040097 ↗
38. Laser Surgery in Management of Medication-Related Osteonecrosis of the Jaws: A Meta-Analysis10.1007/s10006-020-00831-0 ↗
39. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial10.1200/JCO.19.02192 ↗
40. Teriparatide for the Treatment of Medication-Related Osteonecrosis of the Jaw10.1097/MJT.0000000000001182 ↗
41. Bullock, G., Miller, C., McKechnie, A., and Hearnden, V. (2020). Synthetic Hydroxyapatite Inhibits Bisphosphonate Toxicity to the Oral Mucosa in Vitro. Materials, 13.10.3390/ma13092086 ↗
42. Chin, K.-Y., Ekeuku, S.O., and Trias, A. (2022). The Role of Geranylgeraniol in Managing Bisphosphonate-Related Osteonecrosis of the Jaw. Front. Pharmacol., 13.10.3389/fphar.2022.878556 ↗
43. Ferreira, F., Faria, C., and Pozza, D.H. (2025). Autologous Platelet Concentrates in the Management of Medication-Related Osteonecrosis of the Jaw: A Systematic Review. Medicina, 61.10.3390/medicina61081496 ↗
44. The Effectiveness of Autologous Platelet Concentrates in Prevention and Treatment of Medication-Related Osteonecrosis of the Jaws: A Systematic Review10.1016/j.jcms.2024.01.007 ↗
45. Osteotropic Drug Delivery System (ODDS) Based on Bisphosphonic Prodrug. I.v. Effects of Osteotropic Estradiol on Bone Mineral Density and Uterine Weight in Ovariectomized Rats10.3109/10611869808995866 ↗
46. Calcium Phosphate Ceramic Systems in Growth Factor and Drug Delivery for Bone Tissue Engineering: A Review10.1016/j.actbio.2011.11.017 ↗
47. Drug Carriers in Osteoporosis: Preparation, Drug Encapsulation and Applications10.1016/j.ijpharm.2013.01.031 ↗
48. Controlling the Biological Function of Calcium Phosphate Bone Substitutes with Drugs10.1016/j.actbio.2012.06.022 ↗
49. The Use of Hydroxyapatite Bone Substitute Grafting for Alveolar Ridge Preservation, Sinus Augmentation, and Periodontal Bone Defect: A Systematic Review10.1016/j.heliyon.2018.e00884 ↗
50. Calcium Phosphate Porous Pellets as Drug Delivery Systems: Effect of Drug Carrier Composition on Drug Loading and in Vitro Release10.1016/j.jeurceramsoc.2012.01.018 ↗
51. Bioceramics for Drug Delivery10.1016/j.actamat.2012.10.039 ↗
52. Zhang, Y., Shu, T., Wang, S., Liu, Z., Cheng, Y., Li, A., and Pei, D. (2022). The Osteoinductivity of Calcium Phosphate-Based Biomaterials: A Tight Interaction with Bone Healing. Front. Bioeng. Biotechnol., 10.10.3389/fbioe.2022.911180 ↗
53. Calcium Phosphates/Biphosphonates Combinations…Towards a Therapeutic Synergy10.4028/www.scientific.net/KEM.377.99 ↗
54. Bone Graft Materials. An Overview of the Basic Science10.1097/00003086-200002000-00003 ↗
55. Hydroxyapatite Solubility in Simple Inorganic Solutions10.1016/j.archoralbio.2003.12.004 ↗
56. A New Two-Site Model for Hydroxyapatite Dissolution in Acidic Media10.1016/0021-9797(78)90016-4 ↗
57. Chemical Characterization of Hydroxyapatite Obtained by Wet Chemistry in the Presence of V, Co, and Cu Ions10.1016/j.msec.2012.12.075 ↗
58. Human Bone Marrow Stromal Cells: In Vitro Expansion and Differentiation for Bone Engineering10.1016/j.biomaterials.2006.08.025 ↗
59. Calcium Phosphate Cements Improved by Addition of Carbonated Hydroxyapatite Type B10.1016/j.bsecv.2022.05.002 ↗
60. How Smart Do Biomaterials Need to Be? A Translational Science and Clinical Point of View10.1016/j.addr.2012.07.009 ↗
61. Relationship between Bioceramics Sintering and Micro-Particles-Induced Cellular Damages10.1023/B:JMSM.0000021102.68509.65 ↗
62. Cellular Activity of Osteoblasts in the Presence of Hydroxyapatite: An in Vitro Experiment10.1016/0142-9612(91)90025-6 ↗
63. Calcium Phosphate-Based Particles Influence Osteogenic Maturation of Human Mesenchymal Stem Cells10.1016/j.actbio.2008.11.022 ↗
64. Osteotropic Drug Delivery System (ODDS) Based on Bisphosphonic Prodrug. V. Biological Disposition and Targeting Characteristics of Osteotropic Estradiol10.1248/bpb.20.1183 ↗
65. Calcium Phosphate Cements as Drug Delivery Materials10.1016/j.addr.2012.01.008 ↗
66. A Novel Drug Delivery System for Bisphosphonates: Innovative Strategy for Local Treatment of Bone Resorption10.4028/www.scientific.net/KEM.284-286.399 ↗
67. Novel Biomaterials for Bisphosphonate Delivery10.1016/j.biomaterials.2004.05.019 ↗
68. Reaction of Zoledronate with Beta-Tricalcium Phosphate for the Design of Potential Drug Device Combined Systems10.1021/cm702584d ↗
69. Bigi, A., Boanini, E., Bigi, A., and Boanini, E. (2018). Calcium Phosphates as Delivery Systems for Bisphosphonates. J. Funct. Biomater., 9.10.3390/jfb9010006 ↗
70. Thermodynamic Study of the Interaction between Calcium and Zoledronic Acid by Calorimetry10.1016/j.jct.2016.02.005 ↗
71. The Chemical Composition of Synthetic Bone Substitutes Influences Tissue Reactions in Vivo: Histological and Histomorphometrical Analysis of the Cellular Inflammatory Response to Hydroxyapatite, Beta-Tricalcium Phosphate and Biphasic Calcium Phosphate Cer10.1088/1748-6041/7/1/015005 ↗
72. Paulo, S., Laranjo, M., Abrantes, A.M., Casalta-Lopes, J., Santos, K., Gonçalves, A.C., Paula, A.B., Marto, C.M., Sarmento-Ribeiro, A.B., and Carrilho, E. (2019). Synthetic Calcium Phosphate Ceramics as a Potential Treatment for Bisphosphonate-Related Osteonecrosis of the Jaw. Materials, 12.10.3390/ma12111840 ↗
73. Paulo, S., Laranjo, M., Paula, A., Abrantes, A.M., Martins, J., Marto, C.M., Coelho, A., Casalta-Lopes, J., Carvalho, L., and Carrilho, E. (2020). Calcium Phosphate Ceramics Can Prevent Bisphosphonate-Related Osteonecrosis of the Jaw. Materials, 13.10.3390/ma13081955 ↗
74. Mikai, A., Ono, M., Tosa, I., Nguyen, H.T.T., Hara, E.S., Nosho, S., Kimura-Ono, A., Nawachi, K., Takarada, T., and Kuboki, T. (2020). BMP-2/β-TCP Local Delivery for Bone Regeneration in MRONJ-Like Mouse Model. Int. J. Mol. Sci., 21.10.3390/ijms21197028 ↗
75. Tanaka, Y., Aung, K.T., Ono, M., Mikai, A., Dang, A.T., Hara, E.S., Tosa, I., Ishibashi, K., Ono-Kimura, A., and Nawachi, K. (2021). Suppression of Bone Necrosis around Tooth Extraction Socket in a MRONJ-like Mouse Model by E-RhBMP-2 Containing Artificial Bone Graft Administration. Int. J. Mol. Sci., 22.10.3390/ijms222312823 ↗
76. Beta Tricalcium Phosphate, Either Alone or in Combination with Antimicrobial Photodynamic Therapy or Doxycycline, Prevents Medication-Related Osteonecrosis of the Jaw10.1038/s41598-022-20128-4 ↗
77. Sacco, R., Sartoretto, S.C., de Brito Resende, R.F., de Albuquerque Calasans-Maia, J., Rossi, A.M., de Souza Lima, V.H., de Almeida Barros Mourão, C.F., Granjeiro, J.M., Yates, J., and Calasans-Maia, M.D. (2022). The Use of Hydroxyapatite Loaded with Doxycycline (HADOX) in Dentoalveolar Surgery as a Risk-Reduction Therapeutic Protocol in Subjects Treated with Different Bisphosphonate Dosages. Medicina, 59.10.3390/medicina59010046 ↗
78. The Role of Bone Grafts in Preventing Medication-Related Osteonecrosis of the Jaw: Histomorphometric, Immunohistochemical, and Clinical Evaluation in Animal Model10.1177/19433875211048367 ↗
79. Impact of Beta-Tricalcium Phosphate on Preventing Tooth Extraction-Triggered Bisphosphonate-Related Osteonecrosis of the Jaw in Rats10.1038/s41598-023-43315-3 ↗
80. Local E-RhBMP-2/β-TCP Application Rescues Osteocyte Dendritic Integrity and Reduces Microstructural Damage in Alveolar Bone Post-Extraction in MRONJ-like Mouse Model10.3390/ijms25126648 ↗
81. Photodynamic Therapy for Localized Infections—State of the Art10.1016/j.pdpdt.2009.10.008 ↗
82. Direct Stimulation of Osteoclastic Bone Resorption by Bone Morphogenetic Protein (BMP)-2 and Expression of BMP Receptors in Mature Osteoclasts10.1016/S8756-3282(00)00358-6 ↗
83. Renaturation and Purification of Bone Morphogenetic Protein-2 Produced as Inclusion Bodies in High-Cell-Density Cultures of Recombinant Escherichia coli10.1016/S0168-1656(01)00425-4 ↗
84. Imaging Findings in Bisphosphonate-Related Osteonecrosis of Jaws10.1016/j.joms.2008.12.002 ↗
85. Clinical and Diagnostic Imaging of Bisphosphonate-Associated Osteonecrosis of the Jaws10.1259/dmfr/27458726 ↗
86. Bone Scintigraphy and SPECT/CT of Bisphosphonate-Induced Osteonecrosis of the Jaw
87. Quantitative Assessment of Post-Extraction Healing and Alveolar Ridge Remodelling of the Mandible in Female Rats10.1016/j.archoralbio.2003.12.003 ↗
88. Accuracy of Cone Beam Computed Tomography for Periodontal Defect Measurements10.1902/jop.2006.050367 ↗
89. Prospective Biomarker Evaluation in Patients with Osteonecrosis of the Jaw Who Received Bisphosphonates10.1016/j.bone.2013.08.005 ↗
90. Quantitative Scintigraphic Analysis of Pulp Revascularization in Autotransplanted Teeth in Dogs10.1016/j.archoralbio.2010.07.005 ↗
91. Comparison of the Apical Seal on Filled Root Canals with Topseal® vs MTA Fillapex® Sealers: A Quantitative Scintigraphic Analysis10.4236/ojst.2013.32024 ↗
92. Marques-Ferreira, M., Abrantes, A.M., Paula, A., Laranjo, M., Pires, A.S., Caramelo, F., Segura-Egea, J.J., Brito, A., Carvalho, L., and Botelho, M.F. (2023). The Role of Apical Periodontitis Disease in the Development of Bisphosphonate-Related Osteonecrosis of the Jaw: An Animal Study. Dent. J., 11.10.3390/dj11070168 ↗
93. Histomorphologic Characteristics of Bisphosphonate-related Osteonecrosis of the Jaw10.1111/jop.12156 ↗
94. Spatial Heterogeneity in the Canalicular Density of the Osteocyte Network in Human Osteons10.1016/j.bonr.2017.03.001 ↗